CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL
NCT ID: NCT03907241
Last Updated: 2020-10-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
27 participants
INTERVENTIONAL
2016-03-01
2019-09-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Summary for SCGAM-03 in Canada: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (octanorm) in patients with primary immunodeficiency diseases, including (but not limited to) those who have completed the SCGAM-01 trial
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Octanorm 16.5%
octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
Octanorm 16.5%
Human normal immunoglobulin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Octanorm 16.5%
Human normal immunoglobulin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. For adult patients: freely given written informed consent. For patients below the legal age of majority: freely given written informed consent from parents/legal guardians and written informed assent from the child/adolescent in accordance with local requirements.
3. For female patients of child-bearing potential, a negative result in a urine pregnancy test conducted at the Screening visit.
4. Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study.
Either:
SCGAM-01 patients (United States, Canada):
1\. Completion of the main study SCGAM-01, with good tolerance of octanorm (as determined by the investigator).
Or:
De novo patients (Canada only):
1. C-a Age of ≥18 years and ≤75 years.
1C-b Confirmed diagnosis of PI as defined by ESID and PAGID and requiring immunoglobulin replacement therapy due to hypogammaglobulinaemia or agammaglobulinaemia. The exact type of PI should be recorded.
1. C-c Availability of the IgG trough levels of 2 previous SCIG infusions before enrolment, and maintenance of ≥5.0 g/L in the trough levels of these 2 previous infusions.
And:
2\. For adult patients: freely given written informed consent. For patients below the legal age of majority: freely given written informed consent from parents/legal guardians and written informed assent from the child/adolescent in accordance with local requirements.
3\. For female patients of child-bearing potential, a negative result in a urine pregnancy test conducted at the Screening Visit.
4\. Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study.
Exclusion Criteria
2. Exposure to blood or any blood product or derivative, other than IgG used for regular PID treatment, within the 3 months before the first infusion in this study.
3. Planned pregnancy during the course of the study.
* Either:
SCGAM-01 patients (United States, Canada):
1 Subject being without any IgG treatment for period greater than 5 weeks between the last infusion of octanorm in the SCGAM-01 study and the first infusion of octanorm in the SCGAM-03 study.
Or:
De novo patients (Canada only):
1C-a Acute infection requiring intravenous antibiotic treatment within 2 weeks prior to and during the screening period.
1C-b Known history of adverse reactions to IgA in other products.
1C-c Patients with body mass index \>40 kg/m2.
1C-d Ongoing history of hypersensitivity or persistent reactions to blood or plasma derived products, or any component of the investigational product (such as Polysorbate 80).
1C-e Requirement of any routine premedication for IgG administration.
1C-f History of malignancies of lymphoid cells and immunodeficiency with lymphoma.
1C-g Severe liver function impairment (ALAT 3 times above upper limit of normal).
1C-h Known protein-losing enteropathies or proteinuria.
1C-i Presence of renal function impairment (creatinine \>120 μM/L or creatinine \>1.35 mg/dL), or predisposition for acute renal failure (e.g., any degree of pre-existing renal insufficiency or routine treatment with known nephritic drugs).
1C-j Treatment with oral or parenteral steroids for ≥30 days or when given intermittently or as bolus at daily doses ≥0.15 mg/kg.
1C-k Treatment with immunosuppressive or immunomodulatory drugs.
1C-l Live viral vaccination (such as measles, rubella, mumps and varicella) within the last 2 months prior to first infusion of octanorm.
And:
2\. Exposure to blood or any blood product or plasma derivatives, other than SCIG used for regular PID treatment, within the 3 months before the first infusion of octanorm in this study.
3\. Pregnant or nursing women or planned pregnancy during the course of the study.
4\. Treatment with any investigational medicinal product (other than that of SCGAM-01) within 3 months prior to first infusion of octanorm.
5\. Presence of any condition, that is likely to interfere with the evaluation of study medication or satisfactory conduct of the trial.
6\. Known or suspected to abuse alcohol, drugs, psychotropic agents or other chemicals within the past 12 months prior to first infusion of octanorm.
7\. Known or suspected HIV, HCV, or HBV infection.
2 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Octapharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Octapharma Research Site
Irvine, California, United States
Octapharma Research Site
San Diego, California, United States
Octapharma Research Site
Centennial, Colorado, United States
Octapharma Research Site
Papillion, Nebraska, United States
Octapharma Research Site
Toledo, Ohio, United States
Octapharma Research Site
Frisco, Texas, United States
Octapharma Research Site
Edmonton, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol: US and Canada
Document Type: Statistical Analysis Plan
Document Type: Study Protocol: US only
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCGAM-03 -
Identifier Type: -
Identifier Source: org_study_id
NCT02627300
Identifier Type: -
Identifier Source: nct_alias